Interferon-alpha in serum and carcinomatous pleural effusion after repeated intrapleural injections of antitumor agents.
Pleural effusions and sera of two patients with lung cancer were tested after intrapleural injection of OK-432 as an anticancer drug for IFN-alpha activity by biological assay and for IFN-alpha as an antigen by radioimmunoassay. The titers by radioimmunoassay were fairly consistent with those by biological assay, but were usually higher. In Case 1, IFN-alpha was observed fairly early after administration of OK-432 and only in pleural effusions. In Case 2, induction of IFN-alpha at low level was observed late after the first administration of OK-432 both in the pleural effusion and serum and was detected only by radioimmunoassay.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000276:immunology; D000368:Aged; D001688:Biological Products / Q000008:administration & dosage*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000276:immunology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007267:Injections; D007370:Interferon Type I / Q000032:analysis* / Q000097:blood; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D010844:Picibanil / Q000008:administration & dosage*; D010994:Pleura; D010996:Pleural Effusion / Q000276:immunology*
D001688:Biological Products; D007370:Interferon Type I; D008937:Mitomycins; D010844:Picibanil; D016685:Mitomycin